
Oncology
2024-04-10

Antibody-drug conjugates (ADCs) have shown significant efficacy in HER2-positive breast cancer, but the emergence of resistance underscores the need to understand resistance mechanisms. Preclinical models, like the Enhertu-resistant tumor model developed from continuous Enhertu treatment in JIMT-1 tumor tissues in mice, offer insights into resistance mechanisms involving various cellular components within the tumor microenvironment. These models serve as valuable tools for predicting and understanding ADC resistance, aiding in the development of strategies to overcome resistance in clinical settings.
More infomation about blogs

Let us know which event you're attending and we'd be happy to connect with you.